Canopy Growth

Canopy Growth reported Q1 fiscal 2027 revenue of $58.9 million, up 13% year-over-year, with adjusted gross margin improving to 31% and adjusted EBITDA loss narrowing to $2.3 million. The company still recorded a net loss of $10.6 million and free cash outflow widened to $18.6 million, while some sales growth reflected the MTL Cannabis acquisition rather than pure organic expansion. Investors remained cautious given years of cash burn, restructuring and share issuance; management must demonstrate sustained revenue growth, margin gains and falling cash burn before markets reward the stock. » More on finance.yahoo.com

Canopy Growth has received renewed EU‑GMP certification for its production site in Kincardine, Ontario, from the Regierungspräsidium Tübingen. The certification continues to allow shipments of Canada‑grown medical cannabis from Kincardine to European markets and, together with the EU‑GMP facility in Sankt Leon‑Rot, Germany, strengthens the supply chain. The company reported international net revenue growth in its cannabis business of 10% year‑over‑year for Q1 of fiscal 2027 and plans to expand its flower portfolio for patients in Europe. » More on de.investing.com

Canopy Growth presented a turnaround plan at a growth conference focused on better cultivation, strict cost control and intensified expansion in Europe. The company reported Q1 2027 revenue growth of 13% (Europe +10%) and cut costs by more than CAD 30m, lifting gross margin to 31% (+600 basis points). Canopy is targeting a run-rate in Europe of CAD 100–150m (currently ~CAD 40m) and is concentrating on the Canadian market as well as Germany, Poland and the UK, supported by the acquisition of MTL, EU‑GMP certification and a shift to indoor cultivation. » More on de.investing.com

Canopy Growth has restructured its business, cut costs, sold non-core assets like BioSteel, and completed the acquisition of MTL Cannabis while shifting focus toward higher-margin medical cannabis markets. A recent recapitalization left the company with about $131.3 million in net cash at the end of fiscal 2026, improving its balance sheet and financial flexibility. Revenue growth in Canadian and international medical cannabis accelerated, but the company remains unprofitable, faces intense competition and oversupply in Canada, and retains exposure to U.S. legalization risks through its investments. The turnaround is more credible than in prior years but still requires consistent revenue growth and sustainable profitability to be considered complete. » More on finance.yahoo.com

Canopy Growth reported net revenue of C$81.2 million for the quarter ended June 30, 2026, up 13% year-over-year, beating analyst estimates. Adjusted loss per share was C$0.03 and adjusted EBITDA loss narrowed 59% to C$3.2 million, while net loss fell 68% year-over-year. Revenue rose across all businesses—cannabis revenue up 14% (Canada medical +22%, adult-use +10%), international up 10% and Storz & Bickel up 6%—and adjusted gross margin improved to 31% from 25%, driven by sales growth, the MTL Cannabis acquisition and cost savings. Management highlighted continued momentum and clear strategies to drive further growth in key markets, with partial offset from a reduced Veterans Affairs Canada reimbursement rate. » More on finance.yahoo.com